Inovio reports second quarter 2025 financial results and recent business highlights

On track to submit biologics license application (bla) for ino-3107 in 2h25, with the goal of file acceptance by year end completed design verification (dv) testing of cellectra® 5psp device required for bla submission and requested rolling submission from us food and drug administration (fda) continuing to advance commercial preparations for potential launch of ino-3107 in 2026 if approved by fda plymouth meeting, pa. , aug. 12, 2025 /prnewswire/ -- inovio (nasdaq: ino), a biotechnology company focused on developing and commercializing dna medicines to help treat and protect people from hpv-related diseases, cancer, and infectious diseases, today announced its financial results for the second quarter of 2025 and provided an update on recent company developments.
INO Ratings Summary
INO Quant Ranking